Treating dyslipidemia in the elderly

Current Opinion in Lipidology

Volumn 17, Issue 1, 2006, Pages 54-57

  Pohlel, Khan ^a   Grow, Parker ^a   Helmy, Tarek ^a,b   Wenger, Nanette K ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

Author keywords

Aortic stenosis; Cerebrovascular accident; Chronic kidney disease; Diabetes mellitus; Dyslipidemia; Elderly; Metabolic syndrome

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; COLESEVELAM; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; AORTA VALVE DISEASE; AORTA VALVE STENOSIS; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE;

AGED; AGED, 80 AND OVER; AGING; CHRONIC DISEASE; CLINICAL TRIALS; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; GUIDELINES; HUMANS; INCIDENCE; MALE; NATIONAL HEALTH PROGRAMS; PATIENT EDUCATION; UNITED STATES;

EID: 30744438293     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. American Heart Association. Heart disease and stroke statistics - 2005 update. Dallas, Texas: American Heart Association; 2005.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
3. Grundy SM, Cleeman JL, Bairey Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
5. Shepherd PS, Blauw GJ, Murphy MB, et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630.
6. Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361:1149-1158.
7. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE-IT-TIMI 22) Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
8. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435. A randomized, double-blind study of the effects of low (10 mg/dl) and high (80 mg/ dl) doses of atorvastatin in 10 001 patients with stable CHD and LDL < 130 mg/dl showing a significant reduction in major cardiovascular events. The study supported treatment of LDL-C levels to even lower levels than previously recommended.
9. Lindsay RS, Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep 2004; 4:63-68.
10. Davidson MH. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol 2004; 93 (Suppl):3C-11C.
11. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, Sept 2005. This scientific statement reviews the risk factors, criteria for diagnosis, and management strategies for the underlying risk factors and metabolic syndrome.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. Circulation 2003; 107:391-397.
13. Pearson TA, Mensah GA, Alexander RW, et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107:645-651.
14. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55.
15. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41:1364-1372.
16. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137:555-562.
17. Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin N Am 2005; 89:689-699. This review discusses the common association of chronic kidney disease and dyslipidemia and the strong relationship with CVD.
18. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41 (Suppl 3): S1-S91.
19. Wanner C, Krane V, März W, et al. for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. This randomized, double-blind, prospective study of 1255 patients with type 2 diabetes on hemodialysis showed no benefit of atorvastatin 20 mg/dl versus placebo therapy over a 4-year follow-up period. This was despite a lowering of LDL-C to 72 mg/dl, and raised the question of whether statin therapy at this end-stage renal disease may be too late.
20. Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024-2031.
21. Armitage J, Bowman L. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004; 15:439-446.
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
23. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin N Am 2004; 88:897-909.
24. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001; 104:1927-1932.
25. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethyl-glutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104:2205-2209.
26. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95:2262-2270.
27. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88:693-695.
28. Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359:1125-1126.
29. Rosenhek R, Rader F, Gabriel H, et al. Statins but not ACE-inhibitors reduce aortic stenosis progression. Circulation 2003; 108 (Suppl 4):513.
30. Cowell SJ, Newby DE, Prescott PJ, et al. for the Scottish Aortic Stenosis and Lipid Lowering Trial. Impact on Regression (SALTIRE). A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389-2397. This study evaluated atorvastatin 80 mg/dl versus placebo in patients with aortic stenosis in a randomized trial to determine if statin therapy was able to reduce aortic-jet velocity and aortic valve calcium score, a surrogate of progression of aortic stenosis. The study was unable to halt the progression or promote the regression of calcific aortic stenosis in 155 patients over 25 months.
31. Pedersen T, Rossebo A, Skjaerpe T, et al. Design of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Atherosclerosis Suppl 2003; 4:253.
32. Rashidi A, Casscells W, Madjid M, et al. Is it time to prescribe statins to patients with calcified aortic stenosis? Am Heart J 2005; 150:41-45.